Par launches authorized generic Noxafil
Par Pharmaceuticals, a subsidiary of Endo, is offering an authorized generic of Merck Sharp & Dohme’s Noxafil (posaconazole) delayed-release tablets in a dosage strength of 100 mg.
Endo's subsidiary, Endo Ventures, recently entered into an exclusive U.S. supply and distribution agreement with a subsidiary of Merck, allowing Par to launch and distribute an authorized generic of the product.
The agreement also includes rights to posaconazole 40mg/mL oral suspension which Par intends to launch in the coming months.
"Par is pleased to provide patients and providers with access to a lower-cost treatment through our launch of the authorized generic version of Noxafil," said Domenic Ciarico, Endo executive vice president and chief commercial officer, sterile and generics. "We are proud to add this differentiated product to our portfolio."
Endo's subsidiary, Endo Ventures, recently entered into an exclusive U.S. supply and distribution agreement with a subsidiary of Merck, allowing Par to launch and distribute an authorized generic of the product.
The agreement also includes rights to posaconazole 40mg/mL oral suspension which Par intends to launch in the coming months.
"Par is pleased to provide patients and providers with access to a lower-cost treatment through our launch of the authorized generic version of Noxafil," said Domenic Ciarico, Endo executive vice president and chief commercial officer, sterile and generics. "We are proud to add this differentiated product to our portfolio."